Novartis provides $170M to kick off Surface Oncology partnership

John Carroll

Fledgling Cambridge, MA-based startup has pulled off its first Big Pharma deal, grabbing $ 170 million in near-term milestones, an upfront and research support from as it pursues next-gen cancer immuno-therapies.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS